Hostname: page-component-7b7567c8c-m6dxt Total loading time: 0 Render date: 2026-11-19T04:52:58.727Z Has data issue: false hasContentIssue false

Managing the patient with depression and anxiety

Published online by Cambridge University Press:  16 April 2020

DL Dunner
Affiliation:
Department of Psychiatry and Behavioral Sciences, University of Washington, Suite 306, 4225 Roosevelt Way NE, Seattle, Washington98105, USA
GC Dunbar
Affiliation:
Department of Psychiatry and Behavioral Sciences, University of Washington, Suite 306, 4225 Roosevelt Way NE, Seattle, Washington98105, USA
Get access

Summary

The effect of paroxetine on symptoms of anxiety associated with depression were assessed by meta-analysis of data on the use of paroxetine (n = 2963), active control (n = 1151), and placebo (n = 554) in six-week clinical trials. Paroxetine significantly reduced psychic anxiety by comparison with placebo from week 1 and was more effective than active control from week 2. Paroxetine improved somatic anxiety from week 4 of treatment. There was no association between antidepressant therapy and the emergence of anxiety symptoms in patients with little or no baseline anxiety. Paroxetine resolved baseline symptoms of agitation from week 1 of treatment, and both paroxetine and active control prevented the emergence of agitation. There was no difference between placebo and antidepressant therapy in the frequency of adverse events indicative of increased arousal. The results indicate the utility of paroxetine in depressed patients presenting with associated anxiety symptoms.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Submit a response

Comments

No Comments have been published for this article.